Dr. Rasheed Gbadegesin, M.D.
Pediatrics (Pediatrics Physician)
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
MI license 4301083781 -
Student in an Organized Health Care Education/Training Program
MI license 4301083781
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 6 companies reported 14 payments worth $15,450 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $6,668 |
|---|---|
| Novo Nordisk Inc | $5,208 |
| Calliditas Therapeutics US Inc. | $2,618 |
| AstraZeneca UK Limited | $800 |
| Apellis Pharmaceuticals, Inc. | $139 |
| Novo Nordisk Health Care AG | $18.30 |
| Consulting Fee | $15,118 |
|---|---|
| Food and Beverage | $333 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Mar 26, 2025 | Consulting Fee | $3,320 |
| Calliditas Therapeutics US Inc. Nov 19, 2025 | Consulting Fee TARPEYO · NEPHROLOGY | $2,500 |
| Novo Nordisk Inc Feb 26, 2025 | Consulting Fee Rivfloza · Rare Disease | $2,180 |
| Vertex Pharmaceuticals Incorporated Nov 25, 2025 | Consulting Fee | $1,660 |
| Vertex Pharmaceuticals Incorporated Nov 25, 2025 | Consulting Fee | $1,660 |
| Novo Nordisk Inc May 30, 2025 | Consulting Fee Rivfloza · Rare Disease | $1,635 |
| Novo Nordisk Inc Feb 19, 2025 | Consulting Fee Rivfloza · Rare Disease | $818 |
| AstraZeneca UK Limited Nov 20, 2025 | Consulting Fee | $800 |
| Novo Nordisk Inc May 30, 2025 | Consulting Fee Rivfloza · Rare Disease | $545 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $370,193 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Travere Therapeutics, Inc. · Recruiting · NCT05003986 - Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome
Hoffmann-la Roche Limited - Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
Vifor Pharma, Inc. · Recruiting · NCT05766839 - DUPLEX study in FSGS
Travere Therapeutics, Inc. - PoCP study in FSGS
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
Vertex Pharmaceuticals Incorporated - A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidne…
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.